Independent RESPECT-EPA Study Now Third in a Series of Trials to Underscore CV Risk Reduction Benefits of Eicosapentaenoic Acid for Patients --
-- PROMINENT Study Failed to Show CV Risk Reduction Benefit of the Fibrate Class for Statin-Treated High-Risk Patients --
https://finance.yahoo.com/news/amarin-highlights-key-data-presented-130000460.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.